These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome. Siegmund W; Fengler JD; Franke G; Zschiesche M; Eike O; Eike E; Meisel P; Wulkow R Br J Clin Pharmacol; 1991 Oct; 32(4):467-72. PubMed ID: 1958441 [TBL] [Abstract][Full Text] [Related]
4. Debrisoquine hydroxylation and sulfamethazine acetylation in a Chinese population. Xu XM; Jiang WD Zhongguo Yao Li Xue Bao; 1990 Sep; 11(5):385-8. PubMed ID: 2130590 [TBL] [Abstract][Full Text] [Related]
5. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk. Roots I; Drakoulis N; Ploch M; Heinemeyer G; Loddenkemper R; Minks T; Nitz M; Otte F; Koch M Klin Wochenschr; 1988; 66 Suppl 11():87-97. PubMed ID: 2846954 [TBL] [Abstract][Full Text] [Related]
7. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Llerena A; Edman G; Cobaleda J; Benítez J; Schalling D; Bertilsson L Acta Psychiatr Scand; 1993 Jan; 87(1):23-8. PubMed ID: 8424321 [TBL] [Abstract][Full Text] [Related]
8. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. Evans WE; Relling MV Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245 [TBL] [Abstract][Full Text] [Related]
9. Debrisoquine oxidation in Parkinson's disease. Kallio J; Marttila RJ; Rinne UK; Sonninen V; Syvälahti E Acta Neurol Scand; 1991 Mar; 83(3):194-7. PubMed ID: 2031454 [TBL] [Abstract][Full Text] [Related]
10. Genetic predisposition to Balkan endemic nephropathy: ability to hydroxylate debrisoquine as a host risk factor. Nikolov IG; Chernozemsky IN; Idle JR IARC Sci Publ; 1991; (115):289-96. PubMed ID: 1820343 [TBL] [Abstract][Full Text] [Related]
11. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590 [TBL] [Abstract][Full Text] [Related]
12. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439 [TBL] [Abstract][Full Text] [Related]
13. Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. LLerena A; Herraíz AG; Cobaleda J; Johansson I; Dahl ML Clin Pharmacol Ther; 1993 Dec; 54(6):606-11. PubMed ID: 7903915 [TBL] [Abstract][Full Text] [Related]
14. Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism. Turgeon J; Evans WE; Relling MV; Wilkinson GR; Roden DM Br J Clin Pharmacol; 1991 Sep; 32(3):283-8. PubMed ID: 1685663 [TBL] [Abstract][Full Text] [Related]
15. Phenacetin O-deethylase: an activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine? Kahn GC; Boobis AR; Brodie MJ; Toverud EL; Murray S; Davies DS Br J Clin Pharmacol; 1985 Jul; 20(1):67-76. PubMed ID: 4027138 [TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450dbl phenotypes in malignant and benign breast disease. Pontin JE; Hamed H; Fentiman IS; Idle JR Eur J Cancer; 1990; 26(7):790-2. PubMed ID: 2145896 [TBL] [Abstract][Full Text] [Related]
17. Lack of effect of chloroquine on the debrisoquine (CYP2D6 and S-mephenytoin (CYP2C19) hydroxylation phenotypes. Masimirembwa CM; Gustafsson LL; Dahl ML; Abdi YA; Hasler JA Br J Clin Pharmacol; 1996 Apr; 41(4):344-6. PubMed ID: 8730982 [TBL] [Abstract][Full Text] [Related]
18. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls. Sugimura H; Caporaso NE; Shaw GL; Modali RV; Gonzalez FJ; Hoover RN; Resau JH; Trump BF; Weston A; Harris CC Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046 [TBL] [Abstract][Full Text] [Related]
19. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease. Bordet R; Broly F; Destée A; Libersa C Adv Neurol; 1996; 69():97-100. PubMed ID: 8615190 [No Abstract] [Full Text] [Related]
20. Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine. Firkusny L; Gleiter CH Br J Clin Pharmacol; 1994 Apr; 37(4):383-8. PubMed ID: 8018460 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]